Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Clinical Cancer Research, 05/17/2012

Bcl–2 targeting by navitoclax shows limited single–agent activity against advanced and recurrent small cell lung cancers (SCLC). Correlative analyses suggest several putative biomarkers of clinical benefit. Preclinical models support that navitoclax may enhance sensitivity of SCLC and other solid tumors to standard cytotoxics.

Print Article Summary Cat 2 CME Report